Biomarker identification, selection and clinical validation presents many challenges. We can help you solve them.
Biomarkers are pivotal in diagnostics and drug development. Are you finding the most sensitive, specific, and reproducible multi-marker signatures?
Ariana helps you develop robust biomarker signatures and find the best combinations of biomarkers in your data. It’s the only FDA-tested technology that explores the entire combinatorial space to supply you with the best, most cost-effective signatures.
We deliver the actionable information you need to support your development processes: with our KEM® (Knowledge, Extraction, Management) process, we integrate and analyze multi-parametric data to provide you with the most relevant combinations of markers and patient characteristics.
Our platform handles any kind of relevant data you provide, including clinical, imaging, biochemical, NGS/genomic/proteomic/transcriptomic, genetic, patient characteristics and more.
- Identify, optimize and rank your biomarker signatures.
- Find the best companion markers.
- Minimize data overfitting and bias.
- Mine your databases and identify associations between your biomarkers to support your decision processes.
- Save money by reducing the number of parameters you need to measure.
A comprehensive solution
Ariana finds all possible logical biomarker signatures in your data and systematically identify the best subsets of markers to maximize patient coverage and discrimination.
We help you improve disease diagnosis and management, advance clinical development & minimize risk through our unique and proven KEM® data analysis process.
We provide you with a better understanding of even poorly understood diseases by characterizing heterogeneous populations. Using your data, we identify which patients in your cohorts are outliers and which possess specific combinations of characteristics and markers that differentiate them from the rest of the patient population.
Count on our experience
Ariana has expertise in numerous therapeutic areas, as well as in cosmetics & beauty, health, nutrition and medical devices. We have identified validated high-performance signatures in cancers, CNS, neurology, rheumatology, ocular disease, metabolic disease, pediatric diseases, renal disease, infectious diseases and more.
Data overfitting leads to problems with reproducibility. We deliver reproducible, robust signatures by first mining your data to generate all logical signatures and then evaluating each to deliver signatures you can count on.
We can also help you assess the relevance of using multiplex or multimodality signatures so that you can make the best decisions with your budgets.
Faster, cheaper product development and approval